

## AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application.

### **Listing of claims:**

1. – 4. (canceled)

5. (currently amended) An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of:

(a) a mature form of an amino acid sequence ~~selected from the group consisting of~~ SEQ ID NO: 2, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, or 56;

(b) a variant of a mature form of an amino acid sequence ~~selected from the group consisting of~~ SEQ ID NO: 2, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, or 56, wherein said variant consists one or more conservative substitutions to SEQ ID NO: 2, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, or 56 ~~one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of the amino acid residues from the amino acid sequence of said mature form;~~

(c) an amino acid sequence ~~selected from the group consisting of~~ SEQ ID NO: 2, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, or 56;

(d) a variant of an amino acid sequence ~~selected from the group consisting of~~ SEQ ID NO: 2, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, or 56, wherein said variant consists one or more conservative substitutions to SEQ ID NO: 2, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, or 56 ~~one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence; and~~

(e) an amino acid sequence consisting of one or more amino acid substitutions to SEQ ID NO: 2, wherein said substitutions is selected from the group consisting of: Leu to Arg at position 17, Thr to Ala at position 170, Pro to Leu at position 380, and Met to Ile at

~~position 403 a nucleic acid fragment encoding at least a portion of a polypeptide comprising an amino acid sequence chosen from the group consisting of SEQ ID NO: 2, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, or 56, or a variant of said polypeptide, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence; and~~

(f) ~~or a nucleic acid molecule comprising the complement of said nucleic acid sequence (a), (b), (c), (d) or (e).~~

6. – 7. (canceled)

8. (original) The nucleic acid molecule of claim 5, wherein the nucleic acid molecule differs by a single nucleotide from a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, 21, 23, 25, 27, 28, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, or 55.

9. (currently amended) The nucleic acid molecule of claim 5, wherein said nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of:

(a) a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, 21, 23, 25, 27, 28, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, or 55; and

(b) a nucleotide sequence consisting of one or more nucleotide substitutions to SEQ ID NO:1, wherein said substitutions are selected from the group consisting of: T to G at position 87, A to G at position 545, C to T at position 1176, C to T at position 1190, and G to A at position 1246. ~~differing by one or more nucleotides from a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, 21, 23, 25, 27, 28, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, or 55, provided that no more than 20% of the nucleotides differ from said nucleotide sequence;~~

(c) ~~a nucleic acid fragment of (a); and~~

(d) ~~a nucleic acid fragment of (b).~~

10. – 11. (canceled)

12. (currently amended) A vector comprising the nucleic acid molecule of claim ~~44~~ 5.
13. (original) The vector of claim 12, further comprising a promoter operably-linked to said nucleic acid molecule.
14. (original) A cell comprising the vector of claim 12.
15. – 38. (canceled)
39. (original) A pharmaceutical composition comprising the nucleic acid molecule of claim 5 and a pharmaceutically-acceptable carrier.
40. - 41. (canceled)
42. (original) A kit comprising in one or more containers, the pharmaceutical composition of claim 39.
43. – 49. (canceled)